HUT72709A - Method for inhibiting hiv replication using il-4 - Google Patents

Method for inhibiting hiv replication using il-4 Download PDF

Info

Publication number
HUT72709A
HUT72709A HU9500487A HU9500487A HUT72709A HU T72709 A HUT72709 A HU T72709A HU 9500487 A HU9500487 A HU 9500487A HU 9500487 A HU9500487 A HU 9500487A HU T72709 A HUT72709 A HU T72709A
Authority
HU
Hungary
Prior art keywords
hiv
cells
infected
aids
infection
Prior art date
Application number
HU9500487A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9500487D0 (en
Inventor
Jerome Schwartz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HU9500487D0 publication Critical patent/HU9500487D0/hu
Publication of HUT72709A publication Critical patent/HUT72709A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
HU9500487A 1992-08-19 1993-08-17 Method for inhibiting hiv replication using il-4 HUT72709A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93213492A 1992-08-19 1992-08-19

Publications (2)

Publication Number Publication Date
HU9500487D0 HU9500487D0 (en) 1995-04-28
HUT72709A true HUT72709A (en) 1996-05-28

Family

ID=25461831

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9500487A HUT72709A (en) 1992-08-19 1993-08-17 Method for inhibiting hiv replication using il-4

Country Status (22)

Country Link
US (1) US5700461A (2)
EP (1) EP0656785B1 (2)
JP (1) JP2711182B2 (2)
KR (1) KR950702838A (2)
CN (1) CN1086437A (2)
AT (1) ATE163860T1 (2)
AU (1) AU683427B2 (2)
CA (1) CA2142862C (2)
CZ (1) CZ38095A3 (2)
DE (1) DE69317428T2 (2)
ES (1) ES2113549T3 (2)
FI (1) FI950696L (2)
HU (1) HUT72709A (2)
IL (1) IL106717A0 (2)
MX (1) MX9305016A (2)
NO (1) NO950599L (2)
NZ (1) NZ255735A (2)
PL (1) PL307508A1 (2)
SK (1) SK21295A3 (2)
TW (1) TW291439B (2)
WO (1) WO1994004179A1 (2)
ZA (1) ZA936018B (2)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT858343E (pt) 1995-11-02 2004-07-30 Schering Corp Terapia por infusao continua de uma dose baixa de citoquina
US20040132161A1 (en) * 1998-04-20 2004-07-08 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
US20050124645A1 (en) * 1998-04-20 2005-06-09 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
US20030232738A1 (en) * 1998-04-20 2003-12-18 National Jewish Medical And Research Center Method and composition for increasing CD4+ T lymphocyte immune responsiveness
MXPA00012842A (es) * 1998-06-24 2004-06-22 Univ Emory Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
US6734192B1 (en) 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPH02485A (ja) * 1987-08-03 1990-01-05 Yuu Honshiyo 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
ZA912037B (en) * 1990-03-21 1992-03-25 Schering Corp Use of il-4 to enhance immune response to infectious antigenic challenges
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
EP0490006B1 (en) * 1990-12-13 1994-06-22 Schering-Plough Pharmaceutical compositions for the treatment of B-cell malignancies

Also Published As

Publication number Publication date
NZ255735A (en) 1997-06-24
DE69317428T2 (de) 1998-07-02
US5700461A (en) 1997-12-23
TW291439B (2) 1996-11-21
SK21295A3 (en) 1997-01-08
WO1994004179A1 (en) 1994-03-03
CZ38095A3 (en) 1995-12-13
MX9305016A (es) 1994-02-28
ZA936018B (en) 1994-06-13
NO950599D0 (no) 1995-02-17
HU9500487D0 (en) 1995-04-28
FI950696A0 (fi) 1995-02-16
FI950696A7 (fi) 1995-02-16
DE69317428D1 (de) 1998-04-16
JPH07506116A (ja) 1995-07-06
ES2113549T3 (es) 1998-05-01
EP0656785B1 (en) 1998-03-11
EP0656785A1 (en) 1995-06-14
PL307508A1 (en) 1995-05-29
CA2142862C (en) 2000-05-30
AU5007593A (en) 1994-03-15
JP2711182B2 (ja) 1998-02-10
ATE163860T1 (de) 1998-03-15
AU683427B2 (en) 1997-11-13
CA2142862A1 (en) 1994-03-03
IL106717A0 (en) 1993-12-08
CN1086437A (zh) 1994-05-11
NO950599L (no) 1995-02-17
KR950702838A (ko) 1995-08-23
FI950696L (fi) 1995-02-16

Similar Documents

Publication Publication Date Title
De Maeyer et al. Type I interferons
Djeu et al. The effect of immunopharmacological agents on mouse natural cell-mediated cytotoxicity and on its augmentation by poly I: C
Bukowski et al. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo.
AU680858B2 (en) Therapeutic combination containing interferon
HUT72709A (en) Method for inhibiting hiv replication using il-4
KR970007903B1 (ko) 개인의 변형된 2'-5'-올리고아데닐레이트 합성효소 (2'-5')ran-아제 l 천연 방어 시스템을 회복시키기 위한 약학 조성물
Hou et al. Extent of γδ T cell involvement in the pneumonia caused by Sendai virus
Jain et al. Trial of ribavirin for the treatment of HBsAg positive chronic liver disease
Shoenfeld et al. Familial leukopenia among Yemenite Jews.
Domke-Opitz et al. Role of interferon in persistent infection of macrophages with herpes simplex virus
Schanen et al. Correlation between the Anti‐Virus‐Induced Cytopathic Effect Activity of Interferon‐α Subtypes and Induction of MxA Protein In Vitro
Dandoy et al. Mouse genes influence antiviral action of interferon in vivo
Kohl et al. Defective production of antibody to herpes simplex virus in neonates: defective production of T helper lymphokine and induction of suppression
D'Onofrio et al. Modulation of the cell-mediated immune function by interferon α, β or γ can partially reverse the immunosuppression induced by human T-cell leukemia virus I in human cord blood cultures
Stebbing Studies on the mode of action of single-stranded polynucleotides which are antiviral against encephalomyocarditis virus infection of mice
Tumarkin et al. Potentiation of thermal injury in mouse cells by interferon
JPWO2009028573A1 (ja) 血液凝固障害におけるリバビリンの利用
Macchi et al. Protective effect of interferon β on human T cell leukaemia virus type I infection of CD4+ T cells isolated from human cord blood
Kawai A Marked Decrease of Endogenous and Activated Natural Killer Cell Activities in Childhood Acute Lymphoblastic Leukemia
EP1011714A2 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
Baggett et al. Antiviral activity of Bordetella pertussis vaccine-elicited peritoneal exudate cells
Schellekens et al. Interferons, properties and applications
EP0844003A1 (en) Remedy for coxsackie virus b infection
Ho et al. Ribozyme Gene Therapy Targeting Stem Cells for Human Immunodeficiency Virus Infection
ORLIC et al. Hematopoiesis zyxwvutsrqpo

Legal Events

Date Code Title Description
DFD9 Temporary protection cancelled due to non-payment of fee